Updated on 11 September 2014
Mundipharma pain therapies are indicated for analgesic oncological treatment
Singapore: Singapore headquartered Mundipharma has entered the Mexico market by opening its new office and intends to focus on pain management sector for analgesic and oncological treatment needs.
Mundipharma opened offices in Brazil and Colombia in November 2013.
"We are very excited to start formal activities in Mexico and bring Mundipharma's valuable expertise in pain relief to the over 28 million people estimated to suffer from chronic pain in the country today," said Mr Raman Singh, president, Mundipharma Asia-Pacific, Latin America, the Middle East and North Africa.
As the economies of Latin American countries continue to evolve, chronic and non-communicable diseases such as cancer and diabetes have become the leading cause of illness in the region.
Mr Singh stated "Mundipharma is a leader in the science of pain, and we are widely recognized worldwide for medical innovations in this area. Here in Mexico we are eager to start designing and contributing a portfolio of reliable and high-quality analgesic products to relieve the pain suffered by millions of people and their families."